심장 발작 진단 시장 예측(-2032년) : 제품, 검사 유형, 바이오마커, 영상 진단법, 진단 방법, 연령층, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Heart Attack Diagnostics Market is accounted for $12.5 billion in 2025 and is expected to reach $21.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Heart Attack Diagnostics are medical procedures, tests, and devices used to detect and confirm myocardial infarction, a condition caused by restricted blood flow to the heart. These diagnostics include blood tests for cardiac biomarkers, electrocardiograms (ECG), imaging modalities, and stress tests. They help evaluate heart damage, identify blockages, and guide treatment decisions. Accurate and timely heart attack diagnostics are critical for reducing mortality, improving patient outcomes, and preventing complications related to cardiac events.

According to the World Heart Report, cardiovascular diseases continue to affect more than 500 million people across the globe.

Market Dynamics:

Driver:

Increasing adoption of point-of-care testing devices

The market for heart attack diagnostics is spurred by the rising adoption of point-of-care (POC) testing devices, which enable rapid and accurate detection of cardiac biomarkers at bedside or emergency settings. These devices reduce turnaround times significantly, ensuring timely clinical intervention and improved patient outcomes. Growing emphasis on decentralized healthcare and emergency response efficiency strengthens their adoption globally. Furthermore, technological advancements in portable diagnostic platforms support broader accessibility, making POC testing a pivotal driver in the heart attack diagnostics landscape.

Restraint:

Limited access to diagnostics in rural regions

A significant restraint hindering market growth is the limited access to advanced diagnostic facilities in rural and remote regions. Infrastructure gaps, lack of trained healthcare professionals, and high equipment costs restrict adoption of advanced diagnostic tools in these areas. Consequently, delayed detection of cardiac events leads to poor treatment outcomes, widening healthcare disparities. While urban centers benefit from rapid technological adoption, rural healthcare systems continue to face challenges. This disparity slows overall market penetration and limits equitable diagnostic availability.

Opportunity:

Integration of AI-driven diagnostic platforms

The integration of artificial intelligence (AI) into diagnostic systems presents a promising opportunity for the heart attack diagnostics market. AI-enabled platforms enhance interpretation of complex imaging and biomarker data, enabling faster and more accurate detection of myocardial infarction. Growing investments in digital health and predictive analytics support AI adoption across hospital networks. Additionally, AI-driven decision support tools aid clinicians in triage and treatment planning. As AI technologies mature, their integration enhances precision diagnostics, ultimately revolutionizing cardiac care pathways worldwide.

Threat:

Risk of misdiagnosis affecting clinical trust levels

Despite technological advancements, the risk of misdiagnosis remains a critical threat in the heart attack diagnostics market. False positives or negatives in biomarker assays or imaging tests can undermine physician confidence and negatively impact patient safety. Such occurrences may lead to unnecessary treatments or missed interventions, eroding trust in diagnostic systems. Additionally, concerns over variability in test accuracy across different platforms intensify this threat. Sustained clinical validation and standardization are therefore crucial to mitigate risks and preserve diagnostic credibility.

Covid-19 Impact:

The COVID-19 pandemic significantly disrupted the heart attack diagnostics market, with hospitals prioritizing COVID care and delaying elective cardiac testing. Patient reluctance to visit healthcare facilities further reduced diagnostic volumes. However, the crisis accelerated adoption of point-of-care testing and telehealth-driven cardiac monitoring solutions. Post-pandemic recovery has seen renewed emphasis on early cardiac diagnostics, with healthcare systems investing in resilient diagnostic infrastructure. Consequently, COVID-19 served as both a short-term setback and a long-term catalyst for innovation and decentralization in cardiac diagnostics.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, owing to their widespread use in hospitals, diagnostic laboratories, and emergency care centers. Instruments such as analyzers, imaging devices, and biomarker detection systems form the backbone of cardiac diagnostics, ensuring accurate and timely assessments. Growing demand for technologically advanced and automated diagnostic instruments further consolidates their dominance. Moreover, continuous innovation in imaging modalities and biomarker platforms reinforces the instruments segment as the market's leading contributor.

The echocardiogram segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the echocardiogram segment is predicted to witness the highest growth rate, impelled by its non-invasive nature and ability to provide real-time cardiac imaging. The increasing prevalence of cardiovascular diseases and preference for ultrasound-based diagnostics fuel demand. Advancements in 3D and portable echocardiography systems enhance clinical accuracy and accessibility. Additionally, echocardiograms are becoming integral in emergency and outpatient settings for rapid heart function assessment. This convergence of innovation and adoption establishes echocardiography as the fastest-growing diagnostic segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by its expanding patient pool, rising cardiovascular disease prevalence, and growing healthcare infrastructure. Increasing government initiatives to strengthen early disease detection systems further enhance adoption. Moreover, the presence of cost-effective diagnostic solutions in emerging economies boosts accessibility. Rapid urbanization and lifestyle changes exacerbate cardiac risk factors, fueling diagnostic demand. Collectively, these elements position Asia Pacific as the leading regional market in heart attack diagnostics.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high diagnostic awareness, and rapid technology adoption. Strong presence of leading diagnostic companies and extensive R&D investments accelerate innovation in cardiac testing solutions. Favorable reimbursement frameworks support market penetration of advanced diagnostics. Additionally, growing demand for precision diagnostics and digital health integration amplifies adoption. As cardiovascular burden continues to rise, North America emerges as the fastest-expanding regional market.

Key players in the market

Some of the key players in Heart Attack Diagnostics Market include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., GE Healthcare, Philips Healthcare, Bio-Rad Laboratories, Beckman Coulter (Danaher), Thermo Fisher Scientific Inc., Qiagen N.V., Randox Laboratories, Ortho Clinical Diagnostics, Becton, Dickinson and Company, CardioDx Inc., Biomerica Inc., Luminex Corporation, BioMerieux SA, Nova Biomedical, Nihon Kohden Corporation, Response Biomedical Corporation, and Critical Diagnostics.

Key Developments:

In May 2025, Roche Diagnostics (F. Hoffmann-La Roche Ltd) received FDA 510(k) clearance for an enhanced version of its Elecsys(R) Troponin T high-sensitivity test, aimed at providing even more precise risk stratification for patients presenting with chest pain in the emergency department.

In April 2025, Siemens Healthineers announced the U.S. launch of its Atellica(R) CI1900 Integrated Solution, which combines core laboratory and cardiac testing to deliver a consolidated troponin result from a single platform, improving workflow efficiency for heart attack diagnosis.

In March 2025, Abbott Laboratories initiated a major clinical study across 100 sites in the U.S. and Europe to expand the clinical claims for its Alinity i High-Sensitivity Troponin-I assay, focusing on rapid rule-out protocols to help reduce emergency room overcrowding.

Products Covered:

• Instruments
• Consumables
• Software
• Services

Test Types Covered:

• Electrocardiogram (ECG)
• Blood Tests
• Echocardiogram
• Coronary Angiography

Biomarkers Covered:

• Troponin
• Creatine Kinase-MB (CK-MB)
• Myoglobin
• C-Reactive Protein (CRP)
• Brain Natriuretic Peptide (BNP)

Imaging Modalities Covered:

• Echocardiography
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Nuclear Imaging
• X-ray

Diagnosis Methods Covered:

• Laboratory Testing
• Imaging Testing
• Point-of-Care Testing

Age Groups Covered:

• Below 40 Years
• Above 60 Years

Applications Covered:

• Emergency Diagnosis
• Risk Assessment
• Therapy Monitoring
• Research Applications

End Users Covered:

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Research Laboratories

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Heart Attack Diagnostics Market, By Product

• 5.1 Introduction
• 5.2 Instruments
• 5.3 Consumables
• 5.4 Software
• 5.5 Services

6 Global Heart Attack Diagnostics Market, By Test Type

• 6.1 Introduction
• 6.2 Electrocardiogram (ECG)
• 6.3 Blood Tests
• 6.4 Echocardiogram
• 6.5 Coronary Angiography

7 Global Heart Attack Diagnostics Market, By Biomarker

• 7.1 Introduction
• 7.2 Troponin
• 7.3 Creatine Kinase-MB (CK-MB)
• 7.4 Myoglobin
• 7.5 C-Reactive Protein (CRP)
• 7.6 Brain Natriuretic Peptide (BNP)

8 Global Heart Attack Diagnostics Market, By Imaging Modality

• 8.1 Introduction
• 8.2 Echocardiography
• 8.3 Computed Tomography (CT)
• 8.4 Magnetic Resonance Imaging (MRI)
• 8.5 Nuclear Imaging
• 8.6 X-ray

9 Global Heart Attack Diagnostics Market, By Diagnosis Method

• 9.1 Introduction
• 9.2 Laboratory Testing
• 9.3 Imaging Testing
• 9.4 Point-of-Care Testing

10 Global Heart Attack Diagnostics Market, By Age Group

• 10.1 Introduction
• 10.2 Below 40 Years
• 10.3 Above 60 Years

11 Global Heart Attack Diagnostics Market, By Application

• 11.1 Introduction
• 11.2 Emergency Diagnosis
• 11.3 Risk Assessment
• 11.4 Therapy Monitoring
• 11.5 Research Applications

12 Global Heart Attack Diagnostics Market, By End User

• 12.1 Introduction
• 12.2 Hospitals
• 12.3 Diagnostic Centers
• 12.4 Ambulatory Surgical Centers
• 12.5 Research Laboratories

13 Global Heart Attack Diagnostics Market, By Geography

• 13.1 Introduction
• 13.2 North America
  • 13.2.1 US
  • 13.2.2 Canada
  • 13.2.3 Mexico
• 13.3 Europe
  • 13.3.1 Germany
  • 13.3.2 UK
  • 13.3.3 Italy
  • 13.3.4 France
  • 13.3.5 Spain
  • 13.3.6 Rest of Europe
• 13.4 Asia Pacific
  • 13.4.1 Japan
  • 13.4.2 China
  • 13.4.3 India
  • 13.4.4 Australia
  • 13.4.5 New Zealand
  • 13.4.6 South Korea
  • 13.4.7 Rest of Asia Pacific
• 13.5 South America
  • 13.5.1 Argentina
  • 13.5.2 Brazil
  • 13.5.3 Chile
  • 13.5.4 Rest of South America
• 13.6 Middle East & Africa
  • 13.6.1 Saudi Arabia
  • 13.6.2 UAE
  • 13.6.3 Qatar
  • 13.6.4 South Africa
  • 13.6.5 Rest of Middle East & Africa

14 Key Developments

• 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 14.2 Acquisitions & Mergers
• 14.3 New Product Launch
• 14.4 Expansions
• 14.5 Other Key Strategies

15 Company Profiling

• 15.1 Abbott Laboratories
• 15.2 Siemens Healthineers
• 15.3 F. Hoffmann-La Roche Ltd.
• 15.4 GE Healthcare
• 15.5 Philips Healthcare
• 15.6 Bio-Rad Laboratories Inc.
• 15.7 Beckman Coulter (Danaher Corporation)
• 15.8 Thermo Fisher Scientific Inc.
• 15.9 Qiagen N.V.
• 15.10 Randox Laboratories Ltd.
• 15.11 Ortho Clinical Diagnostics
• 15.12 Becton, Dickinson and Company (BD)
• 15.13 CardioDx Inc.
• 15.14 Biomerica Inc.
• 15.15 Luminex Corporation
• 15.16 BioMerieux SA
• 15.17 Nova Biomedical
• 15.18 Nihon Kohden Corporation
• 15.19 Response Biomedical Corporation
• 15.20 Critical Diagnostics